$33,287.61 ownership Payment -- Teva Pharmaceuticals to Dr. Patricia Davis
Teva Pharmaceuticals reports substantial ownership interest payment to Pulmonologist Patricia Davis
This page provides a detailed analysis of a $33,287.61 ownership payment from Teva Pharmaceuticals to Dr. Patricia Davis. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $33,287.61 |
| Payment Type | ownership |
| Payment Nature | Ownership or Investment Interest |
| Pharmaceutical Company | Teva Pharmaceuticals |
| Physician | Dr. Patricia Davis |
| NPI Number | 1890256647 |
| Physician Specialty | Pulmonology |
| Location | Princeton, NJ |
| Date of Payment | 2025-03-31 |
| Conflict Assessment | High -- Significant |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Teva Pharmaceuticals made a $33.3K ownership payment to Patricia Davis, a Pulmonology specialist in Princeton, NJ. Teva Pharmaceuticals reported a significant ownership interest payment of $33,287.61 to Dr. Patricia Davis in Pulmonology. This payment, categorized as 'Ownership or Investment Interest', occurred on March 31, 2025, in Princeton, NJ. The substantial value of this ownership interest may warrant further investigation into the nature of the relationship between Teva Pharmaceuticals and Dr. Davis.
Patient Guidance: What This Payment Means for You
If you are a patient of Dr. Patricia Davis, this information relates to a financial interest she may have in Teva Pharmaceuticals, which could potentially influence prescribing decisions. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Ownership interests can represent a significant financial relationship between pharmaceutical companies and physicians, potentially exceeding typical consulting or speaking fees common in Pulmonology.
Regulatory Context: Sunshine Act Requirements
Physicians must disclose ownership or investment interests in pharmaceutical companies to ensure transparency and identify potential conflicts of interest under the Sunshine Act.
Related Topics
This payment is related to the following healthcare transparency topics:
- ownership-interest
- pharma-payment
- teva-pharmaceuticals
- pulmonology
- physician-payment
- investment-disclosure
Understanding ownership Payments
Ownership and investment interest payments represent dividends, returns, or other financial benefits from physician ownership stakes in pharmaceutical or medical device companies. These relationships represent the most direct form of financial interest and are subject to the strictest reporting requirements under the Sunshine Act.
Frequently Asked Questions About This Payment
What was this $33.3K payment for?
This was a ownership payment of $33.3K from Teva Pharmaceuticals to Patricia Davis, categorized as "Ownership or Investment Interest". The payment was reported under the Sunshine Act (CMS Open Payments).
Does Patricia Davis accept pharmaceutical money?
Yes, Patricia Davis received this $33.3K payment from Teva Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Patricia Davis's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this ownership payment?
A ownership payment of $33.3K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Pulmonology?
To compare this payment against Pulmonology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Pulmonology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Patricia Davis's relationship with Teva Pharmaceuticals?
The payment amount of $33,287.61 is a notable figure for an ownership interest. This $33.3K ownership payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Pulmonology?
The payment type is specifically 'Ownership or Investment Interest', indicating a financial stake rather than a service payment.
What should patients do after learning about this payment?
If you are a patient of Dr. Patricia Davis, this information relates to a financial interest she may have in Teva Pharmaceuticals, which could potentially influence prescribing decisions.
What else should I know about this ownership payment?
The date of payment is in the future (2025-03-31), which is unusual for reported historical data.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.